Transferrin Saturation Provides Prognostic Information Beyond Ferritin in Hyperferritinemic Heart Failure: A MIMIC-IV Retrospective Cohort Study

Heart failure is a condition where the heart struggles to pump enough blood to meet the body's needs, leading to fatigue, breathlessness, and a high risk of death. For decades, doctors have known that many of these patients suffer from iron deficiency, a lack of the mineral essential for carrying oxygen in the blood. To fix this, they often give iron through an IV, but only if tests show the patient is truly low on iron. The standard way to check for this involves looking at a protein called ferritin, which acts like a storage tank for iron in the body. If the tank is full, doctors usually assume the patient has enough iron and do not give them extra. However, ferritin is a tricky indicator because it also rises when the body is fighting inflammation, such as during a severe illness. This means a patient could have a full "tank" on paper but still be unable to use the iron, or conversely, have a full tank that is actually hiding a different kind of problem.

A team of researchers from the First Hospital of Jilin University decided to investigate whether there is a better way to look at iron status in patients who are already very sick. They focused on a specific group: adults admitted to an intensive care unit with heart failure whose ferritin levels were high enough to be considered "iron sufficient" by current rules. Using a massive, publicly available database of hospital records, they examined whether another measurement, known as transferrin saturation, could reveal hidden risks that ferritin alone missed. Transferrin saturation is a measure of how much of the iron-carrying capacity in the blood is actually being used. The researchers wanted to know if patients with high ferritin but high saturation were different from those with high ferritin but low saturation, and if these differences predicted who would survive the year after leaving the hospital.

The study analyzed data from 909 adults who had been admitted to an intensive care unit with heart failure and had their iron levels checked within the first two days of their stay. The researchers sorted these patients into groups based on their ferritin and saturation levels. They found that among the 443 patients with high ferritin, those who also had high transferrin saturation faced a significantly worse outlook than those with low saturation. Specifically, in the group with high ferritin and high saturation, more than half of the patients died within one year. In contrast, the group with high ferritin but low saturation had a much lower death rate, closer to 31 percent. This difference remained significant even after the researchers accounted for how sick the patients were when they arrived, what other diseases they had, and what medications they were receiving.

What makes this finding particularly important is that current medical guidelines treat all patients with high ferritin as having sufficient iron, regardless of their saturation levels. These guidelines suggest that such patients do not need iron treatment and are often excluded from clinical trials testing iron therapies. However, this study suggests that within this "iron sufficient" group, there is a hidden divide. The patients with high saturation were not just surviving less; they were also sicker when they arrived, with higher scores of organ failure and lower use of standard heart medications. Yet, even after adjusting for these factors, the high saturation level itself remained a strong predictor of death. The researchers noted that the level of ferritin alone did not predict who would die; it was the combination of high ferritin and high saturation that signaled the danger.

The team also looked at how well these measurements could predict death compared to other known risk factors. Adding the saturation measurement to their models improved the ability to distinguish between patients who would survive and those who would not, though the improvement was modest. They found that the relationship between saturation and death was fairly steady and linear, meaning that as saturation went up, the risk of death tended to go up, rather than spiking only at a specific high point. Interestingly, when they looked at the individual components of the saturation calculation, the level of iron in the blood seemed to drive the risk more than the total capacity to carry iron. This suggests that the problem might be related to how much iron is circulating in the blood at that moment, rather than just the storage capacity.

Despite these clear patterns, the researchers were careful not to claim that high saturation causes death or that lowering it would save lives. The study was observational, meaning it looked at what happened naturally rather than testing a treatment. The data came from a single point in time early in the hospital stay, and iron levels can fluctuate wildly during severe illness. Furthermore, only a small fraction of eligible patients had their iron levels checked, which means the group studied might not represent all heart failure patients in the intensive care unit. The authors also noted that some measurements were physically impossible, such as saturation levels over 100 percent, which indicates errors in the lab data, but removing these errors did not change the main results.

The study concludes that for patients in the intensive care unit with heart failure and high ferritin, checking transferrin saturation provides extra information that ferritin alone cannot offer. It identifies a subgroup of patients who are at a much higher risk of dying within a year, even though they appear to have enough iron by standard definitions. This suggests that doctors might need to look beyond ferritin to understand the true iron status and risk profile of critically ill patients. While the findings do not prove that changing iron levels will change outcomes, they highlight a gap in current risk assessment tools. The researchers emphasize that these results need to be confirmed in other groups of patients before they can change how doctors treat heart failure, but they offer a compelling reason to reconsider how iron is evaluated in the most vulnerable patients.